A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma

Trial Profile

A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Neovascular glaucoma
  • Focus Registrational; Therapeutic Use
  • Acronyms VEGA
  • Sponsors Bayer
  • Most Recent Events

    • 09 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 29 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 23 May 2016 Planned End Date changed from 1 Jul 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top